Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin

Japanese Journal of Clinical Oncology

Volumn 39, Issue 5, 2009, Pages 315-320

  Yasui, Hirofumi ^a   Yoshino, Takayuki ^b   Boku, Narikazu ^a   Onozawa, Yusuke ^a   Hironaka, Shuichi ^a   Fukutomi, Akira ^a   Yamazaki, Kentaro ^a   Taku, Keisei ^a   Kojima, Takashi ^a   Machida, Nozomu ^a  

^a SHIZUOKA CANCER CENTER   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG APPROVAL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; JAPAN; LEUKOPENIA; MALE; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; RETROSPECTIVE STUDY; SKIN MANIFESTATION; THROMBOCYTOPENIA; VOMITING; WESTERN HEMISPHERE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; OXONIC ACID; PYRIMIDINES; RETROSPECTIVE STUDIES; TEGAFUR;

EID: 65549152765     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyp014     Document Type: Article

References (20)

1. Scheithauer W, Rosen H, Kornek GV, Sebesta C, Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. Br Med J 1993;306:752-5.
2. Poon MA, O'Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407-18.
3. Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37.
4. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, et al. Antitumor activity of 1M tegafur-0.4M 5-chloro-2, 4-dihydroxypyridine-1M potassium oxonate(S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 1996;56:2602-6.
5. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study Group. Br J Cancer 2000;83:141-5.
6. Shirao K, Ohtsu A, Takada H, Mitachi Y, Hirakawa K, Horikoshi N, et al. Phase II study of oral S-1 for treatment of metastatic colorectal carcinoma. Cancer 2004;100:2355-61.
7. Malik ST, Talbot D, Clarke PI, Osborne R, Reznek R, Wrigley PF, et al. Phase II trial of UFT in advanced colorectal and gastric cancer. Br J Cancer 1990;62:1023-5.
8. Takahashi I, Kakeji Y, Emi Y, Sakurai M, Yonemura Y, Kimura Y, et al. S-1 in the treatment of advanced and recurrent gastric cancer: Current state and future prospects. Gastric Cancer 2003;6(Suppl 1):28-33.
9. Jeung HC, Rha SY, Cho BC, Yoo NC, Roh JK, Roh WJ, et al. A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens. Br J Cancer 2006;95:1637-41.
10. Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracilleucovorin: Interim results of a phase III trial. J Clin Oncol 2003; 21:2059-69.
11. Kemeny N, Garay CA, Gurtler J, Hochster H, Kennedy P, Benson A, et al. Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer. J Clin Oncol 2004;22:4753-61.
12. Hoff PM, Pazdur R, Lassere Y, Carter S, Samid D, Polito D, et al. Phase II study of capecitabine in patients with fluorouracil-resistant metastatic colorectal carcinoma. J Clin Oncol 2004;2078-83.
13. Matin K, Jacobs SA, Richards T, Wong MK, Earle M, Evans T, et al. A phase I/II study of trimetrexate and capecitabine in patients with advanced refractory colorectal cancer. Am J Clin Oncol 2005;28:439-44.
14. Gubanski M, Naucler G, Almerud A, Lideståhl A, Lind PA. Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol 2005;44:236-9.
15. Chong G, Dickson JL, Cunningham D, Norman AR, Rao S, Hill ME, et al. Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. Br J Cancer 2005;93:510-4.
16. Lenz HJ, Van Cutsem E, Khambata-Ford S, Mayer RJ, Gold P, Stella P, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-21.
17. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007;357:2040-8.
18. Chen HX, Mooney M, Boron M, Vena D, Mosby K, Grochow L, et al. Phase II multicenter trial of bevacizumab plus fluorouracil and leucovorin in patients with advanced refractory colorectal cancer: An NCI Treatment Referral Center Trial TRC-0301. J Clin Oncol 2006;24:3354-60.
19. Malik I, Hecht JR, Patnaik A, Venook A, Berlin J, Croghan G, et al. Safety and efficacy of panitumumab monotherapy in patients with metastatic colorectal cancer (metastatic colorectal cancer). 2005. ASCO Annual Meeting. Abstract 3520.
20. Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-64.